EXACT SCIENCES CORP (EXAS) Stock News
NASDAQ:EXAS - Nasdaq - US30063P1057 - Common Stock - Currency: USD
EXAS Latest News, Press Relases and Analysis
Exact Sciences Announces Medicare Coverage for Oncodetect™ Molecular Residual Disease Test in Colorectal Cancer
What Makes Exact Sciences (EXAS) a New Buy Stock
Exact Sciences (EXAS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Concerns Rise Over Exact Sciences Corp. (EXAS) Salesforce Reorganization Affecting Growth
Parnassus Investments, an investment management company, released the “Parnassus Growth Equity Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here. In the first quarter, the Fund (Investor Shares) returned -8.59% (net of fees), outperforming the Russell 1000 Growth Index’s -9.97% decline. In the first quarter, post-election optimism, driven by […]
Mentions: CRM
Could Personalized Medicine Be Your Portfolio's Next Big Winner? Find Out
BofA analysts review the promise and limits of AI in precision medicine, highlighting key players like Tempus, Guardant, and Exact Sciences.
Tempus AI's 89% Genomics Surge: Will the Momentum Keep Building?
TEM's Genomics revenues soar 89% on oncology test gains and Ambry Genetics' boost. New assays could fuel more growth.
Hologic Climbs 13% in a Month: How Should You Play the Stock?
HOLX up 13% over the last month, supported by a rejected $16.7 billion buyout offer and new BCI data. What's the investment outlook?
2 Brilliant Stocks to Buy With $200 and Hold for 5 Years
Mentions: TMDX
EXAS Stock Up on Q1 Earnings & Revenue Beat, 2025 Sales View Raised
Exact Sciences ends the first quarter of 2025 on a solid note.
CRISPR Therapeutics (CRSP) Up 11.1% Since Last Earnings Report: Can It Continue?
CRISPR Therapeutics (CRSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Mentions: CRSP
Should You Continue to Hold EXAS Sciences Stock in Your Portfolio?
EXAS rides on strong Cologuard and Oncotype DX growth, but rising costs and high debt may test its staying power.
Exact Sciences Announces Expanded Clinical Validation of the Oncodetect™ Test and Molecular Residual Disease Innovation Roadmap
Exact Sciences to Participate in June Investor Conference
Exact Sciences Highlights Innovations in Early Cancer Detection and Precision Oncology at ASCO 2025
Exact Sciences Corporation (EXAS) Slid on Fear of Competition
Baron Funds, an investment management company, released its “Baron Discovery Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here. In the first quarter, the fund was down 6.17% (Institutional Shares), outperforming the -11.12% return for the Russell 2000 Growth Index. The market began strong in February but faded due […]
2 Brilliant Stocks to Buy With $200 and Hold for 5 Years
Exact Sciences has helped increase colorectal cancer detection. TransMedics Group developed a revolutionary way to store organs before transplants. The company's Organ Care System (OCS) mimics the physiology of the human body, resulting in a higher usage rate for the organs it is approved for -- lungs, hearts, and kidneys -- than the traditional cold storage method.
Will Palantir Stock Join The $1 Trillion Market Cap Club by 2030? The Answer May Surprise You.
Investors are bullish on this AI defense contractor. The numbers tell a different story.
This Top High-Yield Dividend Stock Has a Brilliant Strategy to Capitalize on This Growing Value Disconnect
Brookfield Renewable is always looking for opportunities to grow value for its shareholders. It's seeing a widening disconnect between public and private market values for renewable energy assets. Brookfield is capitalizing on this opportunity through its smart capital recycling strategy.
Exact Sciences Earns 2025 Great Place To Work® Certification™
Tariffs Dim Hologic's 2025 Expectations: Time to Reassess the Stock?
HOLX displays cautious fiscal 2025 guidance in a challenging geopolitical and macroeconomic environment. What does it mean for the stock?
Exact Sciences to Participate in May Investor Conference
Exact Sciences (EXAS) Reports Q1 Loss, Tops Revenue Estimates
Exact Sciences (EXAS) delivered earnings and revenue surprises of 43.24% and 2.53%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: RGNX
Exact Sciences Hikes Its Full-Year Outlook. But There's One First-Quarter Drawback.
The company hiked its sales guidance for the year, but reported steeper-than-expected first-quarter losses.